Multi-center phase II trial of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric and gastro-esophageal cancer

Japanese Journal of Clinical Oncology

Volumn 39, Issue 4, 2009, Pages 237-243

  Sun, Qing ^a   Liu, Chaoying ^a   Zhong, Haijun ^b   Zhong, Baoliang ^c   Xu, Haiyuan ^d   Shen, Wenxiang ^d   Wang, Daoyuan ^e  

^a NANJING MEDICAL UNIVERSITY   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^d JIANGSU UNIVERSITY   (China)

^e SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Advanced gastric cancer; Advanced gastro esophageal cancer; Cisplatin; Paclitaxel; Weekly

Indexed keywords

CAPECITABINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; FLUOROURACIL; FOLINIC ACID; FUWANG; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; OXALIPLATIN; PACLITAXEL; RANITIDINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DIURESIS; DRUG TOLERABILITY; ESOPHAGUS CANCER; FEMALE; FLUID INTAKE; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; RASH; SIDE EFFECT; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TOTAL STOMACH RESECTION; TREATMENT OUTCOME; TREATMENT REFUSAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; PACLITAXEL; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 63849292292     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp008     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
3. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91.
4. Schipper DL, Wagener DJ. Chemotherapy of gastric cancer. Anticancer Drugs 1996;7:137-49.
5. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-8.
6. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-7.
7. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996;56:816-25.
8. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
9. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 1998;4:269-74.
10. Bokemeyer C, Lampe CS, Clemens MR, Hartmann JT, Quietzsch D, Forkmann L, et al. A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer. Anticancer Drugs 1997;8:396-9.
11. Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, et al. A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 2000;83:458-62.
12. Kim MK, Lee KH, Hyun MS, Do YR, Song HS, Lee WS, et al. A multi-center, phase II clinical trial of Padexol (paclitaxel) and cisplatin for patients suffering with advanced gastric cancer. Cancer Res Treat 2005;37:349-53.
13. Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, et al. Weekly, high-dose paclitaxel in advanced lung carcinoma: A phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer 2003;97:2480-6.
14. Seidman AD, Hudis CA, Albanell J, Tong W, Tepler I, Currie V, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998;16:3353-61.
15. Markman M, Hall J, Spitz D, Weiner S, Carson L, Van Le L, et al. Phase II trial of weekly single-agent paclitaxel in platinum/ paclitaxel-refractory ovarian cancer. J Clin Oncol 2002;20:2365-9.
16. Ychou M, Astre C, Rouanet P, Fabre JM, Saint-Aubert B, Domergue J, et al. A phase II study of 5-fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancer. Eur J Cancer 1996;32:1933-7.
17. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, et al. Docetaxel (Taxotere)-cisplatin (TC): An effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 2000;11:301-6.
18. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999;17:319-23.
19. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design. J Natl Cancer Inst 1994;86:1517-24.
20. Reed E, Kohn EC, Sarosy G, Dabholkar M, Davis P, Jacob J, et al. Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results. Semin Oncol 1995;22: 90-6.
21. Rosenberg P, Andersson H, Boman K, Ridderheim M, Sorbe B, Puistola U, et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol 2002;41:418-24.
22. Fennelly D, Aghajanian C, Shapiro F, O'Flaherty C, McKenzie M, O'Connor C, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997;15:187-92.
23. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
24. Murad AM, Petroianu A, Guimaraes RC, Aragao BC, Cabral LO, Scalabu A, et al. Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: A novel, safe, and effective regimen. Am J Clin Oncol 1999;22:580-6.
25. Ridwelski K, Gebauer T, Fahlke J, Kroning H, Kettner E, Meyer F, et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001;12: 47-51.
26. Park SR, Oh DY, Kim DW, Kim TY, Heo DS, Bang YJ, et al. A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer. Oncol Rep 2004;12:1059-64.
27. Seo BG, Oh SY, Lee DM, Yoo HS, Lee S, Kim SG, et al. A phase II study of paclitaxel and cisplatin as salvage therapy for patients with advanced or metastatic gastric cancer. Cancer Res Treat 2007;39:6-9.
28. Lee KW, Im SA, Yun T, Song EK, Na I, Shin H, et al. Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer. Jpn J Clin Oncol 2005;35:720-6.
29. Polee MB, Eskens FA, van der Burg ME, Splinter TA, Siersema PD, Tilanus HW, et al. Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer 2002;86:669-73.
30. Kornek GV, Raderer M, Schu ll B, Fiebiger W, Gedlicka C, Lenauer A, et al. Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer. Br J Cancer 2002;86:1858-63.
31. Yamaguchi K, Shimamura T, Komatsu Y, Takagane A, Yoshioka T, Saitoh S, et al. East Japan Gastric Cancer Study Group. Phase I-II study of biweekly paclitaxel administration with fixed-dose-rate cisplatin in advanced gastric cancer. Gastric Cancer 2006;9:36-43.
32. Kim YH, Yamaguchi K, Bang YJ, Takiuchi H, Kang WK, Sato A, et al. Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea Japan Collaborative Study Group Trial. Jpn J Clin Oncol 2007;37:501-8.
33. Kim JG, Sohn SK, Song HS, Kwon KY, Do YR, Lee KH, et al. Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol 2007;60:863-9.